Phase II randomized, double-blind, multi-center, parallel-group, placebo-controlled multiple-loading dose regimen study to assess the safety, efficacy and duration of response of AIN457 in patients with chronic plaque-type psoriasis.

Trial Profile

Phase II randomized, double-blind, multi-center, parallel-group, placebo-controlled multiple-loading dose regimen study to assess the safety, efficacy and duration of response of AIN457 in patients with chronic plaque-type psoriasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 12 May 2016 Results (pooled analysis of this and other nine studies, n = 3993) assessing safety of secukinumab published in the Journal of the American Academy of Dermatology.
    • 29 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Oct 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top